PMID- 24641448
OWN - NLM
STAT- MEDLINE
DCOM- 20150423
LR  - 20140820
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
VI  - 15
IP  - 8
DP  - 2014 Sep
TI  - Costs of adverse events among patients with HIV infection treated with 
      nonnucleoside reverse transcriptase inhibitors.
PG  - 488-98
LID - 10.1111/hiv.12145 [doi]
AB  - OBJECTIVES: The aim of the study was to assess the incidence and costs of adverse 
      events (AEs) among patients with HIV infection treated with nonnucleoside reverse 
      transcriptase inhibitors (NNRTIs) from the health care system perspective. 
      METHODS: US medical and pharmacy claims during 2004-2009 were examined to select 
      adult new NNRTI users with HIV infection. The incidence of selected AEs and time 
      to occurrence were assessed during the first year. Episodes of care for each AE 
      were identified using claims associated with AE management. For each AE, a 
      propensity score model was used to match patients with an AE to those without 
      (1:4) based on the propensity of having an AE. Mean total health care costs, 
      AE-associated costs and incremental costs per episode, and annual total health 
      care costs per patient were calculated. RESULTS: Of the 2548 NNRTI-treated 
      patients, 29.3% experienced AEs. The incidence ranged from 0.4 episodes/1000 
      person-years for suicide/self-injury to 14.9 episodes/1000 person-years for 
      dizziness, 49.8 episodes/1000 person-years for depression and 150.3 episodes/1000 
      person-years for lipid disorder. The mean AE-associated cost (duration) per 
      episode ranged from $586 (88 days) for lipid disorder to $975 (33 days) for rash, 
      $2760 (73 days) for sleep-related symptoms and $4434 (41 days) for 
      nausea/vomiting. The mean incremental cost per episode ranged from $1580 for rash 
      to $2032 for lipid disorder, $8307 for sleep-related symptoms and $12 833 for 
      nausea/vomiting. During the 12 months following NNRTI initiation, the mean annual 
      total health care cost was $27 299 (efavirenz: $26 185; other NNRTIs: $34 993) 
      and AE-associated costs were $608 (efavirenz: $554; other NNRTIs: $979) among all 
      NNRTI users. CONCLUSIONS: With treatment increasing patient survival, comparisons 
      of therapeutic regimens should consider treatment-associated AEs. Findings from 
      this study could be informative for clinicians and payers in managing HIV 
      infection with NNRTIs.
CI  - (c) 2014 British HIV Association.
FAU - Simpson, K N
AU  - Simpson KN
AD  - Medical University of South Carolina, Charleston, SC, USA.
FAU - Chen, S-Y
AU  - Chen SY
FAU - Wu, A W
AU  - Wu AW
FAU - Boulanger, L
AU  - Boulanger L
FAU - Chambers, R
AU  - Chambers R
FAU - Nedrow, K
AU  - Nedrow K
FAU - Tawadrous, M
AU  - Tawadrous M
FAU - Pashos, C L
AU  - Pashos CL
FAU - Haider, S
AU  - Haider S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140318
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 0 (Reverse Transcriptase Inhibitors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Drug-Related Side Effects and Adverse Reactions/*economics/*epidemiology
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - Health Care Costs
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Reverse Transcriptase Inhibitors/administration & dosage/*adverse effects
MH  - United States
MH  - Young Adult
OTO - NOTNLM
OT  - HIV
OT  - adverse events
OT  - health care costs
OT  - nonnucleoside reverse transcriptase inhibitors
EDAT- 2014/03/20 06:00
MHDA- 2015/04/24 06:00
CRDT- 2014/03/20 06:00
PHST- 2014/01/27 00:00 [accepted]
PHST- 2014/03/20 06:00 [entrez]
PHST- 2014/03/20 06:00 [pubmed]
PHST- 2015/04/24 06:00 [medline]
AID - 10.1111/hiv.12145 [doi]
PST - ppublish
SO  - HIV Med. 2014 Sep;15(8):488-98. doi: 10.1111/hiv.12145. Epub 2014 Mar 18.